1,400
Participants
Start Date
February 2, 2016
Primary Completion Date
September 30, 2026
Study Completion Date
September 30, 2026
SPN-812
"Cohort 'A': Children 6-11 yrs of age take 100-400mg SPN-812 once daily by mouth and adolescents 12-17 yrs of age take 100-600mg SPN-812 once daily by mouth. Pediatric subjects in Cohort 'A' are given a choice to extend their participation in the study every 6 months for up to 72 months.~Cohort 'B': Pre-school-age children 4-5 yrs of age take 100mg SPN-812 once daily by mouth. Pediatric subjects in Cohort 'B' will be treated with 100 mg SPN-812 (100 mg capsule) for up to 6 months."
Sarkis Clinical Trials, Gainesville
Florida Clinical Research Center, LLC., Maitland
Florida Clinical Research Center, LLC, Maitland
Indago Research & Health Center, Inc., Hialeah
Meridien Research at Florida Clinical Research Center, Bradenton
Clinical Neuroscience Solutions, Inc., Memphis
CNS Healthcare, Memphis
Woodland International Research Group, Little Rock
IPS Research, Oklahoma City
Paradigm Research Professionals, Oklahoma City
Bayou City Research Corporation, Houston
Road Runner Research, San Antonio
MCB Clinical Research Centers, LLC, Colorado Springs
Ericksen Research & Development, Clinton
Alliance for Wellness dba Alliance for Research, Long Beach
Northwest Clinical Trials, Bellevue
Supernus Pharmaceuticals, Inc.
INDUSTRY